Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Global distance test

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    122 result(s) found for: Global distance test. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2016-004460-19 Sponsor Protocol Number: P1604GTN Start Date*: 2017-04-20
    Sponsor Name:G. Pohl-Boskamp GmbH & Co.KG
    Full Title: A multi-centre, randomized, placebo-controlled, double-blind trial to assess the efficacy and safety of nitroglycerin sublingual powder on walking distance in a scheduled forced titration design in...
    Medical condition: Peripheral arterial occlusive disease (PAOD, femoro-popliteal stenosis) and intermittent claudication (Fontaine stage IIb, pain-free walking distance < 200 m), lasting for at least 3 months to ensu...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10074576 Peripheral arterial occlusive disease Fontaine stage IIb LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004903-33 Sponsor Protocol Number: IBM4809 Start Date*: 2018-06-18
    Sponsor Name:Orphazyme A/S
    Full Title: Phase 2/3 Study of Arimoclomol in Inclusion Body Myositis (IBM) A Randomized, Double-blind, Placebo-Controlled Trial
    Medical condition: Sporadic Inclusion Body Myositis (sIBM)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10075052 Sporadic inclusion body myositis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-004072-59 Sponsor Protocol Number: 1245-0167 Start Date*: 2018-04-03
    Sponsor Name:Boehringer-Ingelheim España, S.A.
    Full Title: A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In pa...
    Medical condition: Chronic Heart Failure with preserved Ejection Fraction (HFpEF)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) GR (Completed) PT (Completed) PL (Completed) SE (Completed) NO (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004073-14 Sponsor Protocol Number: 1245-0168 Start Date*: 2018-04-03
    Sponsor Name:Boehringer-Ingelheim España, S.A.
    Full Title: A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In pa...
    Medical condition: Chronic Heart Failure with reduced Ejection Fraction (HFrEF)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GR (Completed) PT (Completed) PL (Completed) SE (Completed) NO (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001108-40 Sponsor Protocol Number: MK-5475-007 Start Date*: 2021-04-08
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10065150 Associated with pulmonary arterial hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002069-52 Sponsor Protocol Number: 4045-301 Start Date*: 2017-01-23
    Sponsor Name:Sarepta Therapeutics, Inc.
    Full Title: A Double-Blind, Placebo-Controlled, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
    Medical condition: Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Trial now transitioned) SE (Completed) DE (Completed) FR (Ongoing) ES (Trial now transitioned) CZ (Trial now transitioned) NL (Ongoing) IT (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) IE (Trial now transitioned) DK (Trial now transitioned) GR (Completed) NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-003399-38 Sponsor Protocol Number: NN9535-4533 Start Date*: 2020-08-28
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effects of semaglutide on functional capacity in patients with type 2 diabetes and peripheral arterial disease
    Medical condition: Peripheral arterial disease Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) HU (Completed) NO (Completed) BE (Completed) DK (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003651-12 Sponsor Protocol Number: NAC-E-23 Start Date*: 2005-11-11
    Sponsor Name:ZAMBON, S.A.
    Full Title: NAC EFFECT ON OXIDATIVE STRESS AND MUSCLE FUNCTION IN COPD PATIENTS. Efecto de NAC en estrés oxidativo y función muscular en pacientes con EPOC
    Medical condition: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD).
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-001671-21 Sponsor Protocol Number: KRT-232-101 Start Date*: 2018-10-03
    Sponsor Name:Kartos Therapeutics, Inc.
    Full Title: An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post–ET-MF) Who Have Failed P...
    Medical condition: Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF(Post–ET-MF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077161 Primary myelofibrosis PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074689 Post polycythemia vera myelofibrosis LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074690 Post essential thrombocythemia myelofibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) CZ (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) ES (Trial now transitioned) PL (Trial now transitioned) BG (Trial now transitioned) LT (Trial now transitioned) IT (Trial now transitioned) PT (Trial now transitioned) HR (Trial now transitioned) GR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-002440-14 Sponsor Protocol Number: AC-055-302 Start Date*: 2008-05-15
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: A multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, Phase III study to assess the effects of ACT-064992 on morbidity and mortality in patients with symptomati...
    Medical condition: To assess the effects of ACT-064992 on morbidity and mortality in patients with symptomatic pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064911 Pulmonary arterial hypertension LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) NL (Completed) FR (Completed) FI (Completed) SE (Completed) AT (Completed) DK (Completed) SK (Completed) PT (Prematurely Ended) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-004149-26 Sponsor Protocol Number: METRIS-HF(EMPA) Start Date*: 2018-06-26
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Effect of Metformin and Empagliflozin in insulin resistant patients with heart failure with reduced ejection fraction
    Medical condition: Heart Failure with reduced ejection fraction (HFrEF and HFmrEF)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000106-35 Sponsor Protocol Number: GX29185 Start Date*: 2015-02-02
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDAR...
    Medical condition: Geographic atrophy
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10063947 Geographic atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) AT (Completed) DK (Prematurely Ended) GB (Prematurely Ended) SE (Completed) NL (Prematurely Ended) ES (Completed) BE (Prematurely Ended) PT (Prematurely Ended) SK (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-005126-28 Sponsor Protocol Number: NA Start Date*: 2021-07-01
    Sponsor Name:CHU de Liège
    Full Title: Comparison of ultrasound-guided PENG block and supra-inguinal fascia iliaca compartment block for postoperative pain and early motor recovery after total hip arthroplasty: a randomized controlled n...
    Medical condition: Total hip arthroplasty by postero-lateral approach
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021382-78 Sponsor Protocol Number: RXT-MISO-10 Start Date*: 2011-11-14
    Sponsor Name:Consorci Mar Parc de Salut de Barcelona (Parc de Salut MAR)
    Full Title: Dose radiotherapy for lung cancer treatment.
    Medical condition: Lung cancer.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000107-27 Sponsor Protocol Number: GX29176 Start Date*: 2015-02-02
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDAR...
    Medical condition: Geographic atrophy
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10063947 Geographic atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) AT (Completed) DK (Prematurely Ended) GB (Prematurely Ended) PL (Prematurely Ended) NL (Prematurely Ended) SK (Completed) ES (Completed) BE (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-003438-28 Sponsor Protocol Number: AC-065A308 Start Date*: 2016-03-04
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: The efficacy and safety of initial triple versus initial dual oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension: A multi-center, double-blind, placebo-cont...
    Medical condition: Pulmonary arterial hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NO (Completed) FR (Completed) DK (Completed) AT (Completed) GB (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001642-17 Sponsor Protocol Number: AMB116457 Start Date*: 2013-04-26
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: An open-label extension study of the long-term safety, tolerability and efficacy of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
    Medical condition: Subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH).
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004855 10068739 Chronic thromboembolic pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) DE (Completed) GB (Prematurely Ended) CZ (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002799-26 Sponsor Protocol Number: Start Date*: 2015-10-27
    Sponsor Name:Papworth Hospital NHS Foundation Trust
    Full Title: TRANSFORM-UK: A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension
    Medical condition: Pulmonary arterial hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-000687-33 Sponsor Protocol Number: HOPE Start Date*: 2015-11-18
    Sponsor Name:Leiden University Medical Center
    Full Title: Randomized placebo-controlled trial to investigate clinical efficacy, anti-inflammatory properties and safety of prednisolone in hand osteoarthritis: a proof-of-concept study
    Medical condition: Hand osteoarthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-005536-17 Sponsor Protocol Number: UX007G-CL301 Start Date*: 2017-05-17
    Sponsor Name:Ultragenyx Pharmaceutical Inc
    Full Title: A Phase 3, randomized, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of UX007 in the treatment of movement disorders associated with Glucose Transporter Type 1...
    Medical condition: Glucose Transporter Type 1 deficiency syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10061032 Carbohydrate transport disorder LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) FR (Completed) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 21:01:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA